Zhen Su
Chief Executive Officer & Member Board of Directors Marengo Therapeutics
As CEO of Marengo Therapeutics and a director of the company’s board, Zhen Su brings nearly three decades of experience as a physician-scientist and biopharma executive, with expertise in building and leading both R&D and commercial organizations. During his tenure at Marengo, Zhen has led the team’s progressing the company’s lead asset into clinical trials, grown its leading-edge pipeline, and established a $2.8B strategic partnership with Ipsen. Zhen is also the Founding Chair for the Biotech Committee of the Society for Immunotherapy of Cancer (SITC) and was recently appointed to the Board of Directors at Karyopharm Therapeutics Inc (NASDAQ: KPTI), CytomX Therapeutics (NASDAQ: CTMX) and Galvanize Therapeutics.
Seminars
- Discussing why B-cell targeted therapies alone is often insufficient
- Emphasizing the need to break the T/B-cell axis to modulate T-helper cells that provide survival and differentiation signals for pathogenic B-cells
- Defining the necessary therapeutic precision, selective manipulation or depletion of pathogenic T-cell subsets while preserving the protective, conventional T-cell immunity
Join this session for a candid conversation around the future of T-cell depletion for immune reset:
- Debating the technical feasibility and current limitations of logic-gated CAR-T cells in autoimmunity
- Discussing the emerging paradigm of T-cell modulation vs elimination including the modalities most promising for safely silencing autoreactive T-cells without long-term safety risks
- Effectively measuring the resulting state of functional tolerance
- Exploring the combination of translational biomarkers and clinical trial endpoints necessary to validate the safety and disease specificity of targeted T-cell therapies
